Organovo (NASDAQ:ONVO) Coverage Initiated by Analysts at StockNews.com

Stock analysts at StockNews.com started coverage on shares of Organovo (NASDAQ:ONVO) in a note issued to investors on Thursday. The firm set a “sell” rating on the medical research company’s stock.

Organovo Stock Performance

Shares of NASDAQ:ONVO opened at $0.35 on Thursday. The firm’s 50 day simple moving average is $0.40 and its 200-day simple moving average is $0.47. Organovo has a one year low of $0.32 and a one year high of $1.74. The firm has a market cap of $5.44 million, a PE ratio of -0.33 and a beta of 0.56.

Organovo (NASDAQ:ONVO) last released its quarterly earnings data on Friday, November 8th. The medical research company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.12. Organovo had a negative return on equity of 249.28% and a negative net margin of 12,176.70%. The company had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.04 million. Equities research analysts predict that Organovo will post -0.77 EPS for the current fiscal year.

Organovo Company Profile

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.